to Evaluate the Efficacy and Safety of Eltrombopag for Thrombocytopenia With Chronic HBV Infection
Status:
Recruiting
Trial end date:
2022-07-31
Target enrollment:
Participant gender:
Summary
Primary Objective: To evaluate the efficacy of 6-week Eltrombopag to treat thrombocytopenia
associated with chronic hepatitis B virus infection. Secondary Objective: To evaluate the
efficacy and safety of 6-week and 22-week Eltrombopag to treat thrombocytopenia associated
with chronic hepatitis B virus infection.
Phase:
Phase 2
Details
Lead Sponsor:
Institute of Hematology & Blood Diseases Hospital
Collaborators:
Henan Cancer Hospital North China University of Technology Affiliated Hospital Novartis Qilu Hospital of Shandong University Second Affiliated Hospital of Guangzhou Medical University The Affiliated Hospital of Qingdao University The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School The First Affiliated Hospital of University of Science and Technology of China The Second Affiliated Hospital of Kunming Medical University The Second Hospital of Hebei Medical University Tianjin First Central Hospital Tianjin Medical University Second Hospital